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Introduction {#jah31717-sec-0004}
============

Atherosclerosis is the major cause of cardiovascular disease, and is characterized by chronic inflammation and lipid accumulation in the vasculature.[1](#jah31717-bib-0001){ref-type="ref"}, [2](#jah31717-bib-0002){ref-type="ref"}, [3](#jah31717-bib-0003){ref-type="ref"}, [4](#jah31717-bib-0004){ref-type="ref"}, [5](#jah31717-bib-0005){ref-type="ref"} Macrophages accumulating in atherosclerotic lesions play important roles in the pathobiology of atherosclerosis from the initial lesion development to acute thrombotic complications occurring as a result of vulnerable plaque rupture or superficial erosion.[6](#jah31717-bib-0006){ref-type="ref"} Recently, it was demonstrated that local macrophage proliferation is the dominant cause of macrophage accumulation compared with the recruitment of circulating monocytes in established atherosclerotic lesions.[7](#jah31717-bib-0007){ref-type="ref"}

Budding uninhibited by benzimidazole‐related 1 (BubR1) is a key molecule in the spindle assembly checkpoint. Checkpoint protein complexes containing BubR1 (Mad3 in yeast), Bub3, Mad2, and Cdc20 inactivate the anaphase‐promoting complex/cyclosome (APC/C) until all kinetochores are attached with microtubules in an appropriate manner.[8](#jah31717-bib-0008){ref-type="ref"} When all the kinetochores establish bipolar attachment, APC/C^Cdc20^ degrades securin and cyclin B, and promotes metaphase--anaphase transition.[9](#jah31717-bib-0009){ref-type="ref"} BubR1 dysfunction causes an unequal segregation of chromosomes that results in chromosomal instability.

Baker[10](#jah31717-bib-0010){ref-type="ref"} and Matsumoto[11](#jah31717-bib-0011){ref-type="ref"} et al demonstrated that mice with 10% of normal *BubR1* expression developed progressive aneuploidy, cataracts, lordokyphosis, loss of subcutaneous fat, impaired wound healing, a severely shortened lifespan together with early aging‐associated vascular phenotypes including a reduced number of vascular smooth muscle cells, and impaired endothelial‐dependent relaxation. We previously generated low‐BubR1‐expressing mutant mice (*BubR1* ^*L/L*^ mice) in which *BubR1* expression was reduced to 20% of the normal level and reported that low BubR1 expression almost completely inhibited intimal hyperplasia after carotid ligation by suppressing vascular smooth muscle cell proliferation, which may contribute in part to lesion formation in the early stages of atherosclerosis.[12](#jah31717-bib-0012){ref-type="ref"} However, the proliferative capacity of vascular smooth muscle cells declines with increasing age, ultimately contributing to plaque destabilization and subsequent vessel occlusion.[13](#jah31717-bib-0013){ref-type="ref"}, [14](#jah31717-bib-0014){ref-type="ref"}, [15](#jah31717-bib-0015){ref-type="ref"} The physiological relevance of BubR1 in atherosclerosis is unknown. This study investigated the functional role of BubR1 in atherosclerosis using apolipoprotein E‐deficient mice (*ApoE* ^*−/−*^ mice), a well‐known model of atherosclerosis,[16](#jah31717-bib-0016){ref-type="ref"}, [17](#jah31717-bib-0017){ref-type="ref"} as well as newly generated *BubR1* ^*L/L*^ and *ApoE* ^*−/−*^ mice (*BubR1* ^*L/L*^ *‐ApoE* ^*−/*−^ mice).

Materials and Methods {#jah31717-sec-0005}
=====================

Experimental Animals {#jah31717-sec-0006}
--------------------

All animal experiments were conducted in accordance with experimental protocols approved by the University Committee on Kyushu University Health Science Center (approval No. A25‐229‐0, No. A27‐151‐0). Low‐*BubR1*‐expressing mutant mice (*BubR1* ^*L/L*^ mice) were generated in our laboratory, as previously described.[12](#jah31717-bib-0012){ref-type="ref"} Apolipoprotein E‐deficient mice (*ApoE* ^*−/−*^ mice*)* on a *C57BL/6J* background were obtained from The Jackson Laboratory (Genetics Research, Bar Harbor, ME).

*BubR1* ^*L/L*^ *‐ApoE* ^*−/*−^ mice were then generated by intercrossing *BubR1* ^*L/L*^ mice with *ApoE* ^*−/−*^ mice 7 times. Littermate *BubR1* ^*L/L*^ *‐ApoE* ^*−/−*^ mice and *ApoE* ^*−/−*^ mice were used for the experiments. All mice were genotyped using tail clip samples and the polymerase chain reaction (PCR). Animals were housed under a 12‐hour light and 12‐hour dark regimen. Accelerated atherosclerosis was induced by feeding mice a high‐cholesterol diet (HCD) containing 1.25% cholesterol (D12108C; Research Diets, New Brunswick, NJ) for 12 weeks. For plasma lipid measurements, blood samples were obtained by right ventricle puncture. The blood was immediately transferred to a tube containing heparin and centrifuged at 4°C for 10 minutes. Plasma was separated immediately at 4°C and kept at −80°C until assayed. Lipid analysis was performed by CRC Inc. (Fukuoka, Japan).

Genomic PCR {#jah31717-sec-0007}
-----------

Pieces of mouse tail were digested for 30 minutes at 95°C with 0.05 mol/L NaOH (500 μL). Tris‐EDTA buffer (1 mol/L Tris‐HCl \[pH 8.0\], 10 mmol/L EDTA) was added and the mixture was vortexed. After centrifugation (20 000*g* for 5 minutes), the supernatant containing genomic BubR1 DNA was used for genotyping and amplified using the following primers: mutant forward primer, 5′‐CCTTCCCGCTTCAGTGACAAC‐3′; common reverse primer, 5′‐AGAATCCTGCCGCATCTACCC‐3′; and wild‐type forward primer, 5′‐AGTTCTGGCCCTCGGAATACC‐3′. The amplification protocol involved initial denaturation at 94°C for 30 s; 35 cycles of 94°C for 1 minute, 60°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 5 minutes. The PCR products were fractionated by electrophoresis on 1.5% agarose gels and detected by GelRed (Biotium Inc., San Francisco, CA) staining. The PCR products from *BubR1* ^*+/+*^ and *BubR1* ^*L/L*^ were 475 and 938 bp, respectively.[12](#jah31717-bib-0012){ref-type="ref"} ApoE DNA was used for genotyping and amplified using the following primers: common forward primer, 5′‐GCCTAGCCGAGGGAGAGCCG‐3′; wild‐type reverse primer, 5′‐TGTGACTTGGGAGCTCTGCAGC‐3′; and mutant reverse primer, 5′‐AGTTCTGGCCCTCGGAATACC‐3′. The amplification protocol involved initial denaturation at 94°C for 30 s; 35 cycles of 94°C for 1 minute, 55°C for 1 minute, 72°C for 1 minute, and a final extension at 72°C for 5 minutes. The PCR products were fractionated by electrophoresis on 1.5% agarose gels and detected by ethidium bromide staining. The PCR products from *ApoE* ^*+/+*^ and *ApoE* ^*−/−*^ were 155 and 245 bp, respectively.[18](#jah31717-bib-0018){ref-type="ref"}

RNA Extraction and Quantitative Real‐Time PCR {#jah31717-sec-0008}
---------------------------------------------

Total RNA was extracted using the ISOGEN reagent (Nippon Gene, Tokyo, Japan), according to the manufacturer\'s protocol. Total RNA was reverse‐transcribed to cDNA using SuperScript III First‐strand Super Mix (Invitrogen, Carlsbad, CA). After cDNA was synthesized, *BubR1* expression was analyzed by quantitative real‐time PCR using the TaqMan fluorogenic probe method with TaqMan Fast Universal PCR Master Mix (2×) (Thermo Fisher Scientific Inc., Waltham, MA). PCR involved initial denaturation at 95°C for 5 minutes; 45 cycles of 95°C for 10 s, 60°C for 20 s, and 72°C for 10 s with StepOne Plus Real‐Time PCR System Upgrade system (Thermo Fisher Scientific Inc.). *BubR1* expression was detected using the BubR1 TaqMan probe mix (Mm00437811_m1). *BubR1* expression was normalized to *GAPDH* expression, which was detected with the GAPDH TaqMan probe mix (Mm99999915_g1). Copy numbers of the target cDNA were estimated using a standard curve.

Western Blotting {#jah31717-sec-0009}
----------------

Cell lysates were dissolved by boiling in Laemmli sample buffer (C3228; Sigma‐Aldrich Ireland Limited, Arklow, Ireland) and proteins were separated using SDS‐PAGE on 7.5% (w/v) polyacrylamide gels. The proteins were transferred onto nitrocellulose membranes, and probed with the specified primary antibodies diluted in 4% (w/v) Block Ace (UKB80; DS Pharma Biomedical Co., Ltd, Osaka, Japan) in TBS 0.1% Tween20. Alpha tubulin was used as a loading control. Primary antibodies used were anti‐BubR1 (dilution 1:1000) (NBP1‐19555; Novus Biological, Minneapolis, MN) and mouse anti‐α‐tubulin (1 μg/mL) (ab4074; Abcam, Cambridge, UK). Bound antibody was detected using horseradish peroxidase‐linked anti‐rabbit IgG (dilution 1:5000) (NA934V; GE Healthcare UK Ltd, Little Chalfont, UK). Antibody‐labeled proteins were visualized using enhanced chemiluminescence, ECL prime (RPN2232; GE Healthcare). Exposed films were digitally photographed and subjected to densitometric analysis using Image J (Synoptics Ltd, Cambridge, UK).

Morphometric Analysis and Histopathology {#jah31717-sec-0010}
----------------------------------------

To quantify the extent of the atherosclerotic lesions in the whole aorta, the aortic arch and thoracic aorta were opened longitudinally, stained with Zudan III, and pinned on a black wax surface. The percentage of the plaque area stained by Zudan III compared with the total luminal surface area was quantified. To quantify the extent of the atherosclerotic lesions in the aortic root, approximately 3 serial cross sections (5‐μm thick) of the aortic root were prepared, as previously described by Paigen et al,[19](#jah31717-bib-0019){ref-type="ref"} with a slight modification. Briefly, atherosclerotic lesions in the aortic sinus region were examined at 3 locations, each separated by 100 μm, with the most proximal site starting after the appearance of at least 2 aortic valve leaflets.[20](#jah31717-bib-0020){ref-type="ref"} Serial sections were stained with elastic van Gieson. The largest plaque of the 3 valve leaflets was used for morphological analysis. The necrotic core area was defined as the areas within a lesion that were negative for hematoxylin‐positive nuclei (ie, acellular).[21](#jah31717-bib-0021){ref-type="ref"}

Immunohistochemistry {#jah31717-sec-0011}
--------------------

Serial aortic root sections adjacent to sections stained with elastic van Gieson were deparaffinized, and endogenous peroxidase was blocked by incubation with 0.3% H~2~O~2~ in methanol for 5 minutes. For antigen retrieval, sections were boiled for 20 minutes in citrate buffer (pH 6.0). After blocking with 3% skim milk, sections were incubated overnight at 4°C with anti‐mouse macrophage antibody (sc‐19991; dilution 1:100; Santa Cruz Biotechnology Inc., Santa Cruz, CA), followed by incubation with biotin‐conjugated secondary antibodies (414311; Nichirei Biosciences Inc., Tokyo, Japan). The sections were then washed and treated with avidin‐peroxidase, developed using the diamino benzidine substrate kit (Wako Pure Chemical Industries, Osaka, Japan), and nuclei were counterstained with hematoxylin. Multiple observers blinded to the experiment protocol performed quantitative analysis. All images were captured using a microscope, BZ‐X700 (Keyence, Osaka, Japan) and analyzed using Image J software (freeware; National Institutes of Health, Bethesda, MD).[20](#jah31717-bib-0020){ref-type="ref"}

Double Immunohistochemical Staining {#jah31717-sec-0012}
-----------------------------------

Cell proliferation in atheromatous lesions from aortic valves was assessed using anti‐proliferating cell nuclear antigen (PCNA) antibody (rabbit polyclonal) (ab18197, Abcam). For double immunohistochemical staining, the sections were autoclaved in citrate buffer to restore antigenicity. A monoclonal anti‐macrophage MAC3 antibody (550292; BD Pharmingen, San Diego, CA) and polyclonal anti‐PCNA form antibodies (ab18197, anti‐PCNA antibody \[rabbit polyclonal\]; Abcam) were used as primary antibodies. Normal rabbit IgG (sc‐2027, Santa Cruz) was used for MAC3 antibody negative control. Goat anti‐rabbit IgG (H+L) (highly cross‐adsorbed; Alexa Fluor 488, A11034; Thermo Fisher Scientific Inc.) was used as a secondary antibody for anti‐PCNA. Normal rabbit IgG (sc‐2027, Santa Cruz) was used as the PCNA antibody‐negative control. Goat anti‐rat IgG (H+L) (Alexa Fluor 555, A21434; Thermo Fisher Scientific Inc.) was used as a secondary antibody for anti‐PCNA.

Irradiation and Bone Marrow Transplantation {#jah31717-sec-0013}
-------------------------------------------

Six‐week‐old male *ApoE* ^*−/−*^ and *BubR1* ^*L/L*^ *--ApoE* ^*−/−*^ mice underwent whole‐body lethal irradiation (10 Gy) and 2×10^6^ freshly prepared sterile bone marrow cells obtained from *ApoE* ^*−/−*^ mice and *BubR1* ^*L/L*^ *‐ApoE* ^*−/−*^ mice were injected (via the tail vein), as previously described.[12](#jah31717-bib-0012){ref-type="ref"} Three weeks after bone marrow transplantation, the mice were fed a HCD. The mice were euthanized 12 weeks later and the aortas were obtained and processed, as described above.

Isolation and Culture of Bone Marrow--Derived Macrophages {#jah31717-sec-0014}
---------------------------------------------------------

Murine bone marrow--derived macrophages (BMMs) were obtained from *ApoE* ^*−/−*^ mice or from *BubR1* ^*L/L*^ *‐ApoE* ^*−/−*^ mice using standard procedures.[22](#jah31717-bib-0022){ref-type="ref"}, [23](#jah31717-bib-0023){ref-type="ref"} Mice were euthanized by cervical dislocation. Hind legs were sterilized with 70% ethanol, then clipped outward to expose the hind legs. Muscle tissue was removed from bones, which were then cut at both ends and crushed in a mortar with 5 mL of lymphocyte medium supplemented with 20 mmol/L 4‐(2‐hydroxyethyl)‐1‐piperazine ethane sulfonic acid (HEPES; 17557‐94; Nacalai Tesquet, Inc., Kyoto, Japan). Bone marrow cells were pipetted up and down to form a single‐cell suspension. Mouse monocyte lineage cells were further purified from bone marrow cells using the Purple easySep magnet (StemCell Technologies, Vancouver, Canada) and were then cultured in RPMI1640 Gibco (Thermo Fisher Scientific Inc.) supplemented with 10% heat‐inactivated fetal bovine serum (Sigma‐Aldrich Corp, St. Louis, MO), 50 IU/mL penicillin G, 50 μg/mL streptomycin (Thermo Fisher Scientific Inc.), and 40 ng/mL macrophage--colony‐stimulating factor (PeproTech Inc., Hartford, CT) for 7 days before being used for experiments, with the culture media changed on days 3, 5, 6, and 7.

Isolation and Culture of Peritoneal Macrophages {#jah31717-sec-0015}
-----------------------------------------------

Mouse peritoneal macrophages derived from *BubR1* ^*L/L*^ *‐ApoE* ^*−/−*^ and *ApoE* ^*−/−*^ mice were prepared and grown in RPMI1640 Gibco medium (Thermo Fisher Scientific Inc.) supplemented with 10% fetal bovine serum (Sigma‐Aldrich Corp.), as previously described.[24](#jah31717-bib-0024){ref-type="ref"} After culture for 3 days, nonadherent cells were removed and the adherent cells were used for experiments.

Cell Proliferation Assay {#jah31717-sec-0016}
------------------------

Cell proliferation assays were performed using a Cell Proliferation ELISA, bromodeoxyuridine (colorimetric) kit (1 647 229; Roche Applied Science, Mannheim, Germany), according to the manufacturer\'s instructions and previously published studies.[25](#jah31717-bib-0025){ref-type="ref"}, [26](#jah31717-bib-0026){ref-type="ref"}, [27](#jah31717-bib-0027){ref-type="ref"} Methodological details are summarized in Data S1.

Scratch Assay {#jah31717-sec-0017}
-------------

Macrophages were analyzed as previously described,[28](#jah31717-bib-0028){ref-type="ref"} with a slight modification. Briefly, BMMs were incubated at 37°C for 1 hour. Then, macrophages were plated in a 24‐well tissue culture--treated plate in complete growth medium to attain ≈80% confluency. Cells were allowed to adhere for 2 hours, then scraped with a P‐200 micropipette tip. Nonadherent cells were aspirated, and complete growth media was replaced. Macrophages were then incubated at 37°C, and serial images were captured at designated time points at ×100 magnification. A standardized grid was placed over the images across the breadth of the denuded zone, and cells migrating into this zone were counted in a blinded fashion using Image J software (freeware; National Institutes of Health, Bethesda, MD). Each quantified sample represented counts from 4 different wells with 2 serial images taken per well.[29](#jah31717-bib-0029){ref-type="ref"}

Chemotaxis Assay {#jah31717-sec-0018}
----------------

The chemotactic activity of peritoneal macrophages (4.0×10^6^/mL) in response to 10 ng/mL of the chemokine monocyte chemotactic protein‐1 (M6667‐10UG, Sigma‐Aldrich Inc.) was measured in a 96‐well microchemotaxis Boyden chamber (Chemo‐Tx 101‐5; Neuro Probe Inc., Gaithersburg, MD), as described elsewhere.[20](#jah31717-bib-0020){ref-type="ref"}, [30](#jah31717-bib-0030){ref-type="ref"} Macrophages that had transmigrated through the micropore were stained with trypan blue. The number of macrophages that migrated in response to monocyte chemotactic protein‐1 was counted.

Colony‐forming Units Assay {#jah31717-sec-0019}
--------------------------

Colony‐forming units (CFU) assays of fresh bone marrow cells derived from *BubR1* ^*L/L*^ *‐ApoE* ^*−/−*^ and *ApoE* ^*−/−*^ mice were performed by culturing the cells on methylcellulose medium with recombinant cytokines (Methocult GF M3434; StemCell Technologies). Methocult GF M3434 (1 mL) containing 100 bone marrow cells was plated in a 35‐mm dish (27100; StemCell Technologies). The cells were cultured for 7 days at 37°C in an atmosphere of 5% CO~2~. Colonies containing 50 or more cells were then enumerated. The total number of colonies, CFU‐granulocyte/erythrocyte/macrophage/megakaryocyte (CFU‐GEMM), CFU‐granulocyte/macrophage (CFU‐GM), CFU‐granulocyte (CFU‐G), CFU‐macrophage (CFU‐M), and burst‐forming unit‐erythroid (BFU‐E), was specified based on morphology.[31](#jah31717-bib-0031){ref-type="ref"}

Flow Cytometry {#jah31717-sec-0020}
--------------

All steps were performed at 4°C in the dark. BMMs (5×10^5^) were resuspended in 200 μL of lymphocyte medium supplemented with 20 mmol/L HEPES, then incubated for 10 minutes. Fluorescein isothiocyanate--conjugated anti‐CD11b (11‐0112; eBioscience, San Diego, CA) (diluted 1:500) and Phycoerythrin‐conjugated anti‐F4/80 antibodies (123109; BioLegend, San Diego, CA) (diluted 1:200) were added to the cells and incubated for 30 minutes in the dark. Cells were centrifuged at 300*g* for 5 minutes, washed by centrifugation with 200 μL fresh lymphocyte medium, and resuspended in 300 μL of fresh lymphocyte medium. Cells were analyzed by FACScalibur (Becton Dickinson Biosciences, San Jose, CA).[23](#jah31717-bib-0023){ref-type="ref"} Macrophages were double‐positive for CD11b and F4/80.

Statistical Analysis {#jah31717-sec-0021}
--------------------

All data are expressed as the mean±SEM. For comparison of 2 groups, the statistical significance of differences was determined using an unpaired *t* test. For comparison of 3 or more groups, a 1‐way ANOVA was used. Statistical significance was evaluated using JMP Pro (Ver.11.0.0; SAS Institute Inc., Cary, NC). Values of *P*\<0.05 were considered statistically significant.

Results {#jah31717-sec-0022}
=======

Generation of *BubR1* ^*L/L*^ *‐ApoE* ^*−/−*^ Mice {#jah31717-sec-0023}
--------------------------------------------------

The *BubR1* wild‐type (*BubR1* ^*+/+*^) allele and *BubR1* low allele yielded a 475‐ and a 938‐bp fragment, respectively, as previous study demonstrated[12](#jah31717-bib-0012){ref-type="ref"} (Figure S1A and S1B). The ApoE wild‐type (*ApoE* ^*+/+*^) DNA allele and ApoE^*−/−*^ DNA allele yielded a 155‐ and a 245‐bp fragment, respectively, as previously demonstrated[18](#jah31717-bib-0018){ref-type="ref"} (Figure S1B and S1C).

We then performed quantitative reverse transcription--PCR to determine the relative expression of *BubR1* in the thymus, and confirmed its expression in *BubR1* ^*L/L*^ *‐ApoE* ^*−/−*^ mice as being 19.9±3.0% of that in *ApoE* ^*−*/*−*^ mice (*P*\<0.05; Figure [1](#jah31717-fig-0001){ref-type="fig"}A). Relative *BubR1* expression in other organs of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice compared with *ApoE* ^*−*/*−*^ mice was as follows: aorta 24.7±9.7% (*P*\<0.05; Figure [1](#jah31717-fig-0001){ref-type="fig"}A); white blood cells 15.7±4.6% (*P*\<0.05; Figure [1](#jah31717-fig-0001){ref-type="fig"}A); and heart 20.3±3.9% (*P*\<0.05; Figure [1](#jah31717-fig-0001){ref-type="fig"}A). *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice had a normal appearance and size at birth.

![Generation of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice. A, *BubR1* expression in the thymus of *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice. Data are presented as the mean±SE; \**P*\<0.01 vs *ApoE* ^*−*/*−*^ mice, Student *t* test. n=5, 6 per group, respectively. *BubR1* expression in the aorta of *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^mice, n=5 in each group. *BubR1* expression in white blood cells of *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice, n=5 in each group. *BubR1* expression in the heart of *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice, n=5 in each group. B and C, Western blotting for BubR1 protein in the testis. S1; *ApoE* ^*−*/*−*^ S7; *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^; n=3 in each group. \**P*\<0.05, vs *ApoE* ^*−*/*−*^, Student *t* test. ApoE^*−*/*−*^ indicates apolipoprotein E‐deficient; BubR1, Budding uninhibited by benzimidazole‐related 1.](JAH3-5-e004081-g001){#jah31717-fig-0001}

We performed Western blotting to determine the *BubR1* protein level in the testis. Relative changes in BubR1 protein expression in the *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mouse testis was 21.9±3.3% that in *ApoE* ^*−*/*−*^ (Figure [1](#jah31717-fig-0001){ref-type="fig"}B and [1](#jah31717-fig-0001){ref-type="fig"}C).

Reduced Expression of BubR1 Has No Significant Effect on Serum Lipid Profile {#jah31717-sec-0024}
----------------------------------------------------------------------------

We evaluated serum lipoprotein levels that might affect atherosclerosis development and progression. There were no differences in the blood count of leukocyte subsets, platelets, and erythrocytes between *ApoE* ^*−*/*−*^ mice and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (Table [1](#jah31717-tbl-0001){ref-type="table-wrap"}). *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice had significantly increased serum cholesterol levels after being fed a HCD (Table [2](#jah31717-tbl-0002){ref-type="table-wrap"}). Comparing *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice, there were no significant differences in levels of serum total cholesterol (1031.8±36.5 mg/dL versus 1078.3±83.8 mg/dL, *P*=0.95), low‐density lipoprotein cholesterol (833.0±21.1 mg/dL versus 916.1±76.5 mg/dL, *P*=0.32), high‐density lipoprotein cholesterol (65.7±12.1 mg/dL versus 55.9±4.4 mg/dL, *P*=0.46), and triglycerides (56.6±9.3 mg/dL versus 53.7±7.8 mg/dL, *P*=0.82) after being fed a HCD for 12 weeks (Table [2](#jah31717-tbl-0002){ref-type="table-wrap"}). After bone marrow transplantation (BMT), a HCD for 12 weeks similarly increased the serum total cholesterol and low‐density lipoprotein levels in all groups (Table [3](#jah31717-tbl-0003){ref-type="table-wrap"}). There were no significant differences in the lipid profile between all the groups. In addition, the main phenotypic characteristics of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice were not different from those of *ApoE* ^*−*/*−*^ mice for development and breeding efficiency.

###### 

Complete Blood Counts of *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ Mice

  Measurement                  *ApoE* ^*−*/*−*^   *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^   *P‐*Value[a](#jah31717-note-0003){ref-type="fn"}
  ---------------------------- ------------------ ----------------------------------- --------------------------------------------------
  Red blood cells, ×10^4^/μL   992±19             946±20                              0.10
  White blood cells, /μL       4322±220           4111±278                            0.54
  Neutrophils, %               20.6±2.1           19.2±2.1                            0.59
  Lymphocytes, %               68.7±1.8           68.3±2.1                            0.89
  Monocytes, %                 6.6±0.6            7.8±0.7                             0.21
  Eosinophils, %               3.7±1.3            2.9±0.7                             0.63
  Platelets, ×10^4^/μL         138±6.0            127±14.0                            0.47

ApoE^*−*/*−*^ indicates apolipoprotein E‐deficient; BubR1, Budding uninhibited by benzimidazole‐related 1.

The data are expressed as the mean±SE, n=9 in each group.

Student *t* test.

###### 

Lipid Profiles of *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ Mice

  Measurement                *ApoE* ^*−*/*−*^   *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^                
  -------------------------- ------------------ ----------------------------------- ------------ -------------
  Total cholesterol, mg/dL   449.0±23.7         1031.8±36.5                         431.6±32.2   1078.3±83.8
  LDL cholesterol, mg/dL     282.6±18.1         833.0±21.1                          306.1±14.6   916.1±76.5
  HDL cholesterol, mg/dL     50.6±4.9           65.7±12.1                           41.6±4.9     55.9±4.4
  Triglycerides, mg/dL       82.3±17.2          56.6±9.3                            93.5±33.9    53.7±7.8

The data are expressed as the mean±SE, n=7 in each group. Post indicates after 12 weeks of HCD treatment. Pre indicates at the beginning of 12 weeks of HCD treatment. ApoE^*−*/*−*^ indicates apolipoprotein E‐deficient; BubR1, Budding uninhibited by benzimidazole‐related 1; HCD, high‐cholesterol diet; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.

*P*\<0.05, pre vs post, Student *t* test.

###### 

Lipid Profiles of Bone Marrow--Transplanted Model Mice After 12 Weeks of HCD Treatment

  Measurement                *ApoE* ^*−*/*−*^ *→ApoE* ^*−*/*−*^   *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ *→ApoE* ^*−*/*−*^   *ApoE* ^*−*/*−*^ *→BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^   *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ *→BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^   *P‐*Value[a](#jah31717-note-0007){ref-type="fn"}
  -------------------------- ------------------------------------ ----------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------
  Total cholesterol, mg/dL   1045.5±82.0                          1057.1±60.7                                           1019.1±52.1                                           1046.0±50.1                                                            0.94
  LDL cholesterol, mg/dL     888.4±77.6                           909.4±49.6                                            871.8±52.7                                            879.6±52.9                                                             0.99
  HDL cholesterol, mg/dL     74.5±7.4                             76.8±12.4                                             80.8±7.8                                              77.3±7.2                                                               0.94
  Triglycerides, mg/dL       69.8±13.2                            66.4±8.9                                              62.0±10.4                                             66.3±8.3                                                               0.94

The data are expressed as the mean±SE, n=6 in each group. ApoE^*−*/*−*^ indicates apolipoprotein E‐deficient; BubR1, Budding uninhibited by benzimidazole‐related 1; HCD, high‐cholesterol diet; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.

ANOVA 1‐way method.

Repression of BubR1 Gene Expression Decreases Atherosclerotic Burden in *ApoE* ^*−*/*−*^ Mice {#jah31717-sec-0025}
---------------------------------------------------------------------------------------------

To visualize lipid‐rich atherosclerotic plaques, aortas were stained with Zudan III. As shown in Figure [2](#jah31717-fig-0002){ref-type="fig"}A, *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice exhibited significantly less atherosclerosis compared with *ApoE* ^*−*/*−*^ mice: total aortic coverage, 30.2±3.0% in *ApoE* ^*−*/*−*^ mice versus 8.6±1.1% in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (*P*\<0.05); aortic arch coverage, 48.7±5.0% in *ApoE* ^*−*/*−*^ mice versus 19.4±7.7% in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (*P*\<0.05); and descending aorta coverage, 24.7±7.7% in *ApoE* ^*−*/*−*^ mice versus 6.3±2.2% in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (*P*\<0.05).

![A, Photomicrograph evaluation of en face aortas, stained with Zudan III and quantitative analysis of atherosclerosis in the total aorta, aortic arch, and descending aorta after 12 weeks of a HCD. Data are presented as the mean±SE; \**P*\<0.05 vs *ApoE* ^*−*/*−*^ mice, Student *t* test. n=7, 9 per group, respectively. B through F, Photomicrographs of atherosclerotic plaques in the aortic root stained with HE,EVG,MAC‐3, PSR and α‐SMA. Data are presented as the mean±SE; \**P*\<0.05 vs *ApoE* ^*−*/*−*^ mice, Student *t* test (n=7 of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice and n=9 of *ApoE* ^*−*/*−*^ mice). Scale bar, 200 μm. G and H, Immunofluorescence experiments identified PCNA(+)‐Mac3(+) macrophages within the lesion area of the aortic root. PCNA(+)‐Mac3(+) cells/Mac3(+) cells (%) in the aortic root of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice was significantly reduced compared with those of *ApoE* ^*−*/*−*^ mice. Data are presented as the mean±SE; \**P*\<0.05 vs *ApoE* ^*−*/*−*^ mice, Student *t* test. n=5, 6 per group. ApoE‐/‐ indicates apolipoprotein E‐deficient; BubR1, Budding uninhibited by benzimidazole‐related 1; DAPI, diamidino‐2‐phenylindole; EVG, elastic van Gieson; HCD, high‐cholesterol diet; HE, Hematoxylin‐Eosin; PCNA, proliferating cell nuclear antigen; PSR, Picro‐Sirius Red; SMA, smooth muscle actin.](JAH3-5-e004081-g002){#jah31717-fig-0002}

In another cohort of mice, we quantified the plaque area in elastic van Gieson-- stained cross sections of the aortic root lesions. The lesion area was significantly decreased in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice compared with *ApoE* ^*−*/*−*^ mice (\[6.5±0.5\]×10^5^ μm^2^ versus \[4.7±0.4\]×10^5^ μm^2^, *P*\<0.05; Figure [2](#jah31717-fig-0002){ref-type="fig"}B). The necrotic core area of aortic root lesions was significantly decreased in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice compared with *ApoE* ^*−*/*−*^ mice (\[1.7±0.4\]×10^4^ μm^2^ versus \[3.3±0.3\]×10^4^ μm^2^, *P*\<0.05; Figure [2](#jah31717-fig-0002){ref-type="fig"}C). There were no differences in the percent area of the necrotic core area in aortic lesions (*ApoE* ^*−*/*−*^: 5.1±0.7, *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^: 4.0±0.8 (%); Figure [2](#jah31717-fig-0002){ref-type="fig"}C). Percent area of Mac‐3‐positive macrophages in the aortic root lesions was lower in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice compared with *ApoE* ^*−*/*−*^ mice (30.0±2.7% versus 14.3±2.5%, *P*\<0.05, Figure [2](#jah31717-fig-0002){ref-type="fig"}D). Absolute counts of Mac‐3‐positive macrophages was also lower in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (205.1±16.3 versus 304.1±22.4, *P*\<0.05, Figure [2](#jah31717-fig-0002){ref-type="fig"}D).

There were no differences in collagen content and percent area of collagen in the aortic root lesions between *ApoE* ^*−*/*−*^ mice and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (Figure [2](#jah31717-fig-0002){ref-type="fig"}E). The α‐SMA‐stained cells in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice were significantly reduced compared with those of *ApoE* ^*−*/*−*^ mice (186.4±8.4 versus 220.6±9.5, *P*\<0.05; Figure [2](#jah31717-fig-0002){ref-type="fig"}F). PCNA(+)‐Mac3(+) cells/Mac3(+) cells (%) in the aortic root of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice were significantly reduced compared with those of *ApoE* ^*−*/*−*^ mice (71.0±6.8% versus 52.8±2.7%, *P*\<0.05 Figure [2](#jah31717-fig-0002){ref-type="fig"}G and [2](#jah31717-fig-0002){ref-type="fig"}H).

BubR1 Insufficiency in Bone Marrow--Derived Cells Results in Attenuated Atherogenesis {#jah31717-sec-0026}
-------------------------------------------------------------------------------------

To determine whether *BubR1* in leukocytes contributed to atherosclerosis, we performed a BMT experiment.

We performed BMT from *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ as a donor to *ApoE* ^*−*/*−*^ as a recipient (*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^) and BMT from *ApoE* ^*−*/*−*^ as a donor to *ApoE* ^*−*/*−*^ as a recipient (*ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^); from *ApoE* ^*−*/*−*^ as a donor to *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ as a recipient (*ApoE* ^*−*/*−*^→*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^); and from *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ as a donor to *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ as a recipient (*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^→*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^). Figure [3](#jah31717-fig-0003){ref-type="fig"}A shows results of Zudan III‐stained atherosclerotic plaques after BMT. A significant reduction was observed in the atherosclerotic lesion area between *ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ mice (6.6±1.7% versus 3.5±0.7%; *P*\<0.05) and between *ApoE* ^*−*/*−*^→*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^→*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ mice (2.4±0.3% versus 1.3±0.2%; *P*\<0.05).

![Effect of bone marrow transplantation on the atherosclerosis lesion area in *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ mice. A, Photomicrographs of the en face evaluation of *ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^, *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^, *ApoE* ^*−*/*−*^→*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^→*BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ mouse aortas stained with Zudan III, and quantitative analysis of atherosclerosis of the total aorta after 12 weeks of a HCD. Data are presented as the mean±SE; \**P*\<0.05, Student *t* test, n=6 in each group. B, Atherosclerosis lesion area of mice in the aortic root lesion, stained with EVG. Data are presented as the mean±SE; \**P*\<0.05, Student *t* test; n=6 in each group. C, Necrotic core lesion area of mice in the aortic root lesion stained with HE. Data are presented as the mean±SE; \**P*\<0.05, Student *t* test; n=6 in each group. D, Mac3‐positive absolute cell count in the aortic root lesion area of mice. Data are presented as the mean±SE; \**P*\<0.05, Student *t* test; n=6 in each group. ApoE^*−*/*−*^ indicates apolipoprotein E‐deficient; BubR1, Budding uninhibited by benzimidazole‐related 1; EVG, elastic van Gieson; HCD, high‐cholesterol diet; HE, Hematoxylin‐Eosin.](JAH3-5-e004081-g003){#jah31717-fig-0003}

Figure [3](#jah31717-fig-0003){ref-type="fig"}B shows elastic van Gieson staining of the aortic root in these BMT mice. Lesion area was significantly decreased in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ mice compared with *ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ mice (\[7.3±0.8\]×10^5^ μm^2^ versus \[11.0±1.5\]×10^5^ μm^2^, *P*\<0.05). Figure [3](#jah31717-fig-0003){ref-type="fig"}C shows HE staining of the aortic root in these BMT mice. The necrotic core area, defined as those areas within a lesion that were negative for hematoxylin‐positive nuclei (ie, acellular), of *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ mice, was significantly reduced compared with *ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ mice (\[1.7±0.1\]×10^4^ μm^2^ versus \[5.0±0.7\]×10^4^ μm^2^, *P*\<0.05). Absolute counts of Mac‐3‐positive macrophages were also lower *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ compared with *ApoE* ^*−*/*−*^→*ApoE* ^*−*/*−*^ (290±19 versus 348±22, *P*\<0.05, Figure [3](#jah31717-fig-0003){ref-type="fig"}D).

Evaluation of the bone marrow replacement rate using C57BL/6J (recipient) and green fluorescent protein (donor) mice revealed that recipient mice had 98.6±0.2% of their total monocyte cells derived from the donor mice (n=5; Figure S2).

Repression of Macrophage BubR1 Expression Impairs Proliferation, but Not Migration, of Macrophages {#jah31717-sec-0027}
--------------------------------------------------------------------------------------------------

Peritoneal macrophages and BMMs were used to evaluate the proliferative capacity of macrophages. Bone marrow cells were cultured ex vivo, as described above. We confirmed induction of the differentiation to macrophages by flow cytometry using anti‐CD11b and anti‐F4/80 antibodies. There were no differences in the serum macrophage--colony‐stimulating factor levels in ApoE^*−*/*−*^ mice (5.8±0.2 ng/mL) and BubR1^L/L^‐ApoE^*−*/*−*^ mice (6.4±0.4 ng/mL; *P*=0.27). Repression of BubR1 expression in both peritoneal macrophages and BMMs inhibited the macrophage--colony‐stimulating factor‐induced proliferation (*P*\<0.05; Figure [4](#jah31717-fig-0004){ref-type="fig"}A).

![In vitro macrophage assay. A, Cell proliferation was slower in *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ peritoneal macrophages (white bar) than in *ApoE* ^*−*/*−*^ macrophages (black bar; n=6 in each group); \**P*\<0.05, Student *t* test. B, Cell proliferation was slower in *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ macrophage‐derived bone marrow cells (white bar) than in *ApoE* ^*−*/*−*^ macrophages (black bar; n=5 in each group). MCP‐1 concentration was 10 ng/mL; *P*\<0.05 Student *t* test. C, Migration capacity was not significantly different between *ApoE* ^*−*/*−*^ macrophages (black bar) and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ macrophages (white bar; n=4 in each group). Student *t* test, NS, not significant. ApoE^*−*/*−*^ indicates apolipoprotein E‐deficient; BrdU, bromodeoxyuridine; BubR1, Budding uninhibited by benzimidazole‐related 1; MCP‐1, monocyte chemotactic protein‐1; M‐CSF, macrophage colony‐stimulating factor.](JAH3-5-e004081-g004){#jah31717-fig-0004}

We assessed the macrophage migration using a classic chemotaxis assay. Migration capacity of macrophages was not significantly different between *ApoE* ^*−*/*−*^ mice and *BubR1* ^*L/L*^‐*ApoE* ^*−*/*−*^ mice (*P*=0.374; Figure [4](#jah31717-fig-0004){ref-type="fig"}B).

Finally, we assessed the migration capacity of macrophages using a scratch assay. Migration capacity of macrophages was not significantly different between macrophages from *ApoE* ^*−*/*−*^ mice and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (*P*=0.70; Figure [4](#jah31717-fig-0004){ref-type="fig"}C).

We performed CFU assays to clarify whether normally developed and functionally indifferent macrophage progenitors exist in both groups. We counted CFU‐GEMM, CFU‐GM, CFU‐G, CFU‐M, and BFU‐E colonies. Colony counts for BFU‐E, CFU‐GM, CFU‐G, CFU‐M, CFU‐GEMM, and the overall number were (*ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^, respectively): 6.0±0.79 and 4.8±0.54; 21.8±3.2 and 21.6±2.0; 24±1.9 and 21±1.4; 12.4±1.8 and 10.6±1.3; 1.6±0.44 and 1.0±0.22; and 65.8±4.5 and 59.0±4.4, respectively. There were no significant functional development differences between the groups (*P*=0.40, 0.95~~4~~, 0.21, 0.40, 0.26; Figure [5](#jah31717-fig-0005){ref-type="fig"}).

![CFU assay of whole bone marrow cells from *ApoE* ^*−*/*−*^ and *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice. Colony counts represent total number from 2 plates. Data are presented as the mean±SE; \**P*\<0.05, Student *t* test. n=5 in each group. ApoE^*−*/*−*^ indicates apolipoprotein E‐deficient; BFU, burst‐forming unit; BubR1, Budding uninhibited by benzimidazole‐related 1; CFU, colony‐forming units; CFU‐G, CFU‐granulocyte; CFU‐GEMM, CFU‐granulocyte/erythrocyte/macrophage/megakaryocyte; CFU‐GM, CFU‐granulocyte/macrophage; CFU‐M, CFU‐macrophage.](JAH3-5-e004081-g005){#jah31717-fig-0005}

Discussion {#jah31717-sec-0028}
==========

We generated novel apolipoprotein E‐deficient (*ApoE* ^*−*/*−*^) and low‐*BubR1*‐expressing mutant (*BubR1* ^*L/L*^) mice (*BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice) to investigate the functional role of BubR1 in atherosclerosis These mice showed no increase in serum cholesterol levels when the mice were fed a HCD.

Our novel findings in this study are summarized as follows: (1) repression of the *BubR1* gene expression decreased the atherosclerotic burden in *ApoE* ^*−*/*−*^ mice; and (2) repression of macrophage *BubR1* expression impaired proliferation, but not migration, of macrophages.

BubR1, a cell cycle--related protein, is a key molecule in the spindle assembly checkpoint.[8](#jah31717-bib-0008){ref-type="ref"} Previous studies demonstrated that BubR1 insufficiency in mice caused phenotypic changes reminiscent of vascular aging.[11](#jah31717-bib-0011){ref-type="ref"}, [12](#jah31717-bib-0012){ref-type="ref"} We tested the hypothesis that BubR1 insufficiency in hyperlipidemic *ApoE* ^*−*/*−*^ mice would exacerbate atherosclerosis as a result of vascular cell senescence. Contrary to our hypothesis, we found that arterial lesions were significantly reduced in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice fed a HCD, and that this was accompanied by a reduction in macrophage accumulation in atherosclerotic plaques. Reduced BubR1 expression did not affect serum cholesterol levels, ruling out the possibility that hypercholesterolemia contributes to alterations of atherogenesis in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice.

As described in (1), we found that suppression of BubR1 impaired atherosclerosis, as shown using Zudan III stain (Figure [2](#jah31717-fig-0002){ref-type="fig"}A). Macrophages play a key role by mediating inflammation, and accelerating atherosclerosis.[21](#jah31717-bib-0021){ref-type="ref"}, [22](#jah31717-bib-0022){ref-type="ref"} Previous studies suggested that recruitment/infiltration of circulating monocytes into the vascular wall causes the accumulation of macrophages in atherosclerotic plaques.[23](#jah31717-bib-0023){ref-type="ref"}, [24](#jah31717-bib-0024){ref-type="ref"}, [25](#jah31717-bib-0025){ref-type="ref"}, [26](#jah31717-bib-0026){ref-type="ref"}, [27](#jah31717-bib-0027){ref-type="ref"}, [28](#jah31717-bib-0028){ref-type="ref"}, [29](#jah31717-bib-0029){ref-type="ref"}, [30](#jah31717-bib-0030){ref-type="ref"} However, recent research has indicated that macrophage accumulation does not only depend on the recruitment/infiltration of circulating monocytes, and in some inflammatory contexts, local macrophage proliferation is dominant.[7](#jah31717-bib-0007){ref-type="ref"} These results suggest that macrophage self‐renewal is a novel therapeutic target to treat cardiovascular diseases.[7](#jah31717-bib-0007){ref-type="ref"}, [31](#jah31717-bib-0031){ref-type="ref"}

To determine whether insufficiency of BubR1 contributes to macrophage accumulation, we investigated the relationship between BubR1 and macrophages. We performed immunohistochemistry of Mac‐3 in atherosclerotic lesions at the aortic root of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice and *ApoE* ^*−*/*−*^ mice fed HCD for 12 weeks. BubR1 insufficiency reduced Mac‐3‐positive macrophage numbers in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice (Figure [2](#jah31717-fig-0002){ref-type="fig"}D).

We showed that the number of macrophages that were proliferating in the heart was decreased in vivo (Figure [2](#jah31717-fig-0002){ref-type="fig"}G and [2](#jah31717-fig-0002){ref-type="fig"}H). Areas of arteriosclerosis were found to be reduced in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice because of a decrease in the number of proliferating macrophages. These results suggest that insufficiency of BubR1 suppresses local proliferation of macrophages or the recruitment of circulating monocytes.

To confirm that macrophage BubR1 regulates atherosclerosis, we performed a BMT study. As shown in Figure [3](#jah31717-fig-0003){ref-type="fig"}A, we suppressed atherosclerosis induced by BubR1 insufficiency in bone marrow----derived cells including monocytes.

To clarify the effect of BubR1 insufficiency on macrophage function, we differentiated macrophages from bone marrow cells. There was an experimental limitation in harvesting macrophages from aortic plaques because it was difficult to harvest and culture pure macrophage cells. Therefore, we performed bone marrow and peritoneal macrophage assays instead of using aortic macrophages. Figure [4](#jah31717-fig-0004){ref-type="fig"}A and [4](#jah31717-fig-0004){ref-type="fig"}B shows that the proliferation of BubR1‐insufficient macrophages was markedly suppressed compared with control macrophages, but that this did not contribute to macrophage migration (Figure [4](#jah31717-fig-0004){ref-type="fig"}C), as described in (2). This result is consistent with tight control of cell proliferation by cell cycle regulators including BubR1.[8](#jah31717-bib-0008){ref-type="ref"}, [10](#jah31717-bib-0010){ref-type="ref"}

Host cells, such as macrophages, smooth muscle cells, and T cells, seem to play major roles in inducing arteriosclerosis, because the percentage of atherosclerotic plaques decreased when host cell *BubR1* expression was reduced, as shown in Figure [3](#jah31717-fig-0003){ref-type="fig"}A. However, we also demonstrated that bone marrow macrophages have a role in inducing arteriosclerosis. We discovered, for the first time, that smooth muscle cells and also macrophages are involved in the reduction of arteriosclerosis in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice.

In summary, we generated *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice, in which BubR1 expression was ≈20% of that in *ApoE* ^*−*/*−*^ mice. We used these mice to examine the role of BubR1 in atherosclerotic lesion development. We found that reduced BubR1 expression in *ApoE* ^*−*/*−*^ mice inhibits macrophage accumulation and atherosclerotic lesion development in metabolically challenged *ApoE* ^*−*/*−*^ mice. In vivo and in vitro data suggested that decreased macrophage proliferation may be a mechanism of reducing macrophage accumulation in *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice. Our data suggest that BubR1 is a promising therapeutic target to prevent atherosclerotic lesion development and devastating life‐threatening complications including acute myocardial infarction. Further studies are needed to clarify the effect of BubR1 insufficiency on bone marrow transfer into mice with established lesions or pharmaceutical interference during late‐stage atherosclerosis.
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**Data S1.** Supplemental material and methods.

**Figure S1.** Mechanism involved in the reduction of protein expression by low‐expression alleles generated by cryptic splicing. A, Schematic diagram of BubR1^L/L^ mice gene. B, PCR of *BubR1* ^*L/L*^ *‐ApoE* ^*−*/*−*^ mice genomic DNA confirms the presence of mutant (938‐bp fragment) *BubR1* genomic DNA and the presence of mutant (245‐bp fragment) *ApoE* genomic DNA. C, Schematic diagram of ApoE^*−*/*−*^ mice gene.

**Figure S2.** We evaluated the bone marrow replacement rate using C57BL/6J (recipient) and green fluorescent protein (donor) mice by FACS. Dot plots show side scatter vs eGFP. The recipient mice had 98.6±0.2% of total monocytes derived from donor mice (n=5 in each group).
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